Target intelligence / Profile preview

Pathogenic bacteria associated with bacterial vaginosis

Molecular classification
Other (heterogeneous mix of bacteria, including anaerobic and facultative anaerobic genera and species)
01

Overview

Pathogenic bacteria associated with bacterial vaginosis refer to a diverse mix of **anaerobic and facultative anaerobic bacteria** that cause a shift from the normal, Lactobacillus-dominated vaginal microbiota to a community dominated by **Gardnerella vaginalis, Atopobium vaginae (now Fannyhesaea vaginae), Mobiluncus species, Prevotella species, Megasphaera, Sneathia, and others**[1][2][3][5]. This dysbiotic bacterial community forms polymicrobial biofilms, raises vaginal pH, and degrades protective mucin, making the vaginal environment more susceptible to inflammation and other infections[1][5][7]. The composition is variable between individuals, but the presence and abundance of Gardnerella and Atopobium are particularly associated with diagnosis and recurrence risk. While some bacterial species within this group are targets for antibiotic therapy, the group as a whole does not constitute a single, well-defined drug target, and management is complicated by recurrence and emerging antibiotic resistance[1][7].

Other names
BV-associated bacteriabacterial vaginosis microbiotaBV microbiotaBV pathogens
02

Mechanism of action

Antibacterial (disruption of bacterial cell wall synthesis or function by drugs like metronidazole and clindamycin). Biofilm disruption (emerging therapeutic strategies, not standard drugs).

03

Biological functions

Disruption of normal vaginal floraFormation of polymicrobial biofilmIncreased vaginal pHMucin degradationImmune modulation (linked with increased risk of other infections)
04

Disease associations

Infection (specifically, bacterial vaginosis)Risk factor for sexually transmitted infections (STIs)Adverse reproductive and obstetric outcomes
05

Safety considerations

High recurrence rates after antibiotic therapyAntibiotic resistance in certain species (notably Atopobium vaginae)Disruption of beneficial microfloraIncreased susceptibility to other infections (including HIV and other STIs)
06

Interacting drugs

Metronidazole

2 more in the full profile.

07

Biomarkers

Presence/abundance of Gardnerella vaginalisPresence/abundance of Atopobium vaginaeDetection of Megasphaera, Prevotella, Sneathia, and other specific BVAB (bacterial vaginosis-associated bacteria)Decreased Lactobacillus spp. compared to pathogenic species

Beyond the preview

Go deeper on Pathogenic bacteria associated with bacterial vaginosis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pathogenic bacteria associated with bacterial vaginosis.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call